Chronic low-grade inflammation, often called "inflammaging," is now recognized as a central driver of biological aging, contributing to cardiovascular disease, neurodegeneration, insulin resistance, and loss of muscle mass
The complete list of substances being removed from Category 2 is as follows: BPC-157 Cathelicidin LL-37 Dihexa Acetate Emideltide (DSIP) Epitalon GHK-Cu (for injectable routes of administration) KPV Mechano Growth Factor, Pegylated (PEG-MGF) Melanotan II MOTs-C Semax (heptapeptide) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) Of these, the substances not scheduled for consideration at the upcoming meeting in July (Cathelicidin LL-37, Dihexa Acetate, GHK-Cu (injectable routes of administration), Mechano Growth Factor Pegylated (PEG-MGF), and Melanotan II) are slated for separate PCAC consultation before the end of February 2027
Buyer Note: BPC-157 is currently classified under WADA's S0 category (Unapproved Substances) and is prohibited in competitive sport
Because it contains no therapeutic drug, it functions only as a preparation solution